{
    "title": "AB 623",
    "content": "The people of the State of California do enact as follows:\n\n\nSECTION 1.\nThe Legislature finds and declares the following:\n(a) Prescription and over-the-counter (OTC) drugs are, after marijuana and alcohol, the most commonly abused substances by Americans over 14 years of age.\n(b) Over two million people in the United States suffer from substance use disorders related to prescription opioid pain relievers.\n(c) More people die from overdoses of prescription opioid pain relievers than from all other drugs combined, including heroin and cocaine.\n(d) Prescription opioid pain relievers can have effects similar to heroin when taken in doses or in ways other than prescribed, and research now suggests that abuse of these drugs may lead to heroin abuse.\n(e) Prescription opioid pain relievers can be particularly dangerous when snorted, injected, or combined with other drugs or alcohol.\nSEC. 2.\nSection 4069 is added to the Business and Professions Code, to read:\n4069.\n(a) A pharmacist shall inform a patient receiving an opioid analgesic drug product on proper storage and disposal of the drug.\nThis information may be included as part of the oral consultation required under Section 1707.2 of Title 17 of the California Code of Regulations.\nThe board shall adopt regulations to implement this section.\n(b) For purposes of this section, \u201copioid analgesic drug product\u201d has the same meaning as defined in Section 1367.217 of the Health and Safety Code.\nSEC. 3.\nSection 1367.217 is added to the Health and Safety Code, to read:\n1367.217.\n(a) Where an abuse-deterrent opioid analgesic drug product is available, a health care service plan shall not require the use of opioid analgesic drug products without the abuse-deterrent properties in order to access abuse-deterrent opioid analgesic drug products.\n(b) This section shall not be construed to prevent a health care service plan from applying prior authorization requirements to abuse-deterrent opioid analgesic drug products, provided that those same requirements are applied to versions of those opioid analgesic drug products without the abuse-deterrent properties.\n(c) A health care service plan shall allow a provider to prescribe, and if otherwise covered, shall provide coverage for, a less than 30-day supply of an opioid analgesic drug product.\n(d) For purposes of this section, the following definitions shall apply:\n(1) \u201cAbuse-deterrent opioid analgesic drug product\u201d means a brand or generic opioid analgesic drug product approved by the federal Food and Drug Administration with abuse-deterrence labeling claims that indicate the drug product is expected to result in a meaningful reduction in abuse.\n(2) \u201cOpioid analgesic drug product\u201d means a drug product in the opioid analgesic drug class that is prescribed to treat moderate to severe pain or other conditions, whether in immediate release or extended release or long-acting form and whether or not combined with other drug substances to form a single drug product or dosage form.\nSEC. 4.\nSection 10123.203 is added to the Insurance Code, to read:\n10123.203.\n(a) Where an abuse-deterrent opioid analgesic drug product is available, an insurer shall not require the use of opioid analgesic drug products without the abuse-deterrent properties in order to access abuse-deterrent opioid analgesic drug products.\n(b) This section shall not be construed to prevent an insurer from applying prior authorization requirements to abuse-deterrent opioid analgesic drug products, provided that those same requirements are applied to versions of those opioid analgesic drug products without the abuse-deterrent properties.\n(c) An insurer shall allow a provider to prescribe, and if otherwise covered, shall provide coverage for, a less than 30-day supply of an opioid analgesic drug product.\n(d) For purposes of this section, the following definitions shall apply:\n(1) \u201cAbuse-deterrent opioid analgesic drug product\u201d means a brand or generic opioid analgesic drug product approved by the federal Food and Drug Administration with abuse-deterrence labeling claims that indicate the drug product is expected to result in a meaningful reduction in abuse.\n(2) \u201cOpioid analgesic drug product\u201d means a drug product in the opioid analgesic drug class that is prescribed to treat moderate to severe pain or other conditions, whether in immediate release or extended release or long-acting form and whether or not combined with other drug substances to form a single drug product or dosage form.\nSEC. 5.\nNo reimbursement is required by this act pursuant to Section 6 of Article XIII\u2009B of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIII\u2009B of the California Constitution."
}